Patient Experience Report

GLP-1 and SGLT-2 Adoption and Retention in Patients with Diabetes

We've tapped into the largest and most clinically representative diabetes patient database in the US, comprising over 60,000 individuals living with diabetes. This report unveils the reasons behind patient decisions regarding the starting, switching, and stopping of GLP-1 and SGLT-2 treatments.

What you get

Reliable data empowering your organization to confidently make strategic decisions.
  • 1,500+ US adults with type 2 diabetes

  • 40% non-white participants

  • 50% male / 50% female respondents